Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...
Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus...
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited...
NEW YORK--(BUSINESS WIRE)--Sep 19, 2023--
Labeling for Biosimilar and Interchangeable Biosimilar Products